AstraZeneca breast cancer drug meets primary and secondary endpoints in new trial
15th Aug 2022 07:27
(Sharecast News) - Drugmaker AstraZeneca said on Monday that positive high-level results from a new trial of its Enhertu breast cancer drug had demonstrating a "statistically significant and clinically meaningful improvement" in progression-free survival.
Read moreAstraZeneca, Daiichi's Enhurtu gets US approval to treat lung cancer
12th Aug 2022 07:04
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu drug has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer, the companies said on Friday.
Read moreAstraZeneca gets US approval for breast cancer treatment
8th Aug 2022 09:49
(Sharecast News) - AstraZeneca's breast cancer treatment candidate 'Enhertu', or trastuzumab deruxtecan, has been approved in the United States, it announced on Monday.
Read moreAstraZeneca breast cancer drug receives EU approval
4th Aug 2022 08:52
(Sharecast News) - Drugmaker AstraZeneca's Lynparza has received European Union approval for use in the adjuvant treatment of adult patients with high-risk early-stage breast cancer, including those with germline BRCA mutations.
Read moreShoreCap stays at 'buy' on AstraZeneca, sees further upgrades ahead on product pipeline
29th Jul 2022 12:45
(Sharecast News) - Analysts at ShoreCap reiterated their 'buy' recommendation for shares of drugs giant AstraZeneca, describing its second quarter top-line growth of 37% year-on-year at constant exchange rates "impressive".
Read moreAstraZeneca raises FY revenue guidance, names new chairman
29th Jul 2022 07:07
(Sharecast News) - Drugmaker AstraZeneca raised full-year revenue guidance on Friday as it provided details of its "strong" first trading half and announced that Michel Demaré would take over as the group's chairman in April 2023.
Read moreFriday preview: US inflation data, AstraZeneca in the spotlight
28th Jul 2022 12:22
(Sharecast News) - All eyes at the end of the week will be on a slew of inflation indicators due out in the US.
Read moreAstraZeneca GMG drug recommended for EU approval
25th Jul 2022 07:56
(Sharecast News) - AstraZeneca said its treatment for the rare autoimmune neuromuscular disease generalised myasthenia gravis (GMG) has been recommended for marketing authorisation in the European Union as an add-on to standard therapy for adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
Read moreAstraZeneca asthma drug gets EU marketing approval
25th Jul 2022 07:43
(Sharecast News) - AstraZeneca's asthma treatment Tezspire has been recommended for marketing authorisation in the European Union as an add-on therapy in patients 12 years and older, the company said.
Read moreAstraZeneca breast cancer drug granted priority review by US FDA
25th Jul 2022 07:12
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Enhertu metastatic breast cancer asset had been granted priority review status in the US following results from its DESTINY-Breast04 trial.
Read moreAstraZeneca breast cancer drug granted priority review by US FDA
25th Jul 2022 07:12
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Enhertu metastatic breast cancer asset had been granted priority review status in the US following results from its DESTINY-Breast04 trial.
Read moreAstraZeneca's HER2-positive breast cancer drug receives EU approval
19th Jul 2022 07:02
(Sharecast News) - Drugmaker AstraZeneca's Enhertu has received European Union approval to be used as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
Read moreAstraZeneca agrees to acquire TeneoTwo
5th Jul 2022 07:04
(Sharecast News) - Drugmaker AstraZeneca has agreed to acquire TeneoTwo and its clinical-stage T-cell engager in a deal worth up to $1.26bn as part of an effort to accelerate the development of the potential new medicine for B-cell haematologic malignancies.
Read moreCovid-19 cases surge during latest week due to BA.4 and BA.5 Covid-19 sub-variants
1st Jul 2022 13:22
(Sharecast News) - The number of new coronavirus cases in Britain jumped again during the preceding week, likely due to the more infectious BA.4 and BA.5 variants of the Omicron variant of Covid-19.
Read moreOxford Biomedica signs new Covid vaccine deal with AstraZeneca
1st Jul 2022 07:03
(Sharecast News) - Oxford Biomedica has signed a new three-year deal to make AstraZeneca's Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.
Read more